serdemetan

Serdemetan is an orally bioavailable small molecule that functions as an antagonist of HDM2 (also known as Mdm2), a negative regulator of the tumor suppressor protein p53. By inhibiting the binding of HDM2 to p53, serdemetan blocks proteasome-mediated degradation of p53, thereby restoring p53 signaling and promoting apoptosis in tumor cells. In addition to its effects on the p53 pathway, serdemetan also disrupts the Mdm2-HIF1α axis, leading to decreased levels of HIF1α and its downstream targets involved in glycolysis and angiogenesis. Serdemetan was developed by Johnson & Johnson Pharmaceutical R&D for potential antineoplastic activity and has been investigated primarily for cancer indications such as neoplasms and glioblastoma[1][2][3][6].

Other names

N1-(2-(1H-indol-3-yl)ethyl)-N4-(pyridin-4-yl)benzene-1,4-diamine881202-45-5